| 2025 | 2024 | |||
|---|---|---|---|---|
| Gross margin | -119,9 k € | -1.4% | -118,3 k € | |
| EBITDA | -119,9 k € | -0.9% | -118,8 k € | |
| Operating profit | -120,4 k € | -0.1% | -120,2 k € | |
| Profit/loss | -120,4 k € | -0.1% | -120,3 k € | |
| Equity | 419,3 k € | +99.9% | 209,7 k € | |
| Total assets | 502,7 k € | +107.9% | 241,7 k € | |
| Cash | 451,6 k € | +99.0% | 226,9 k € | |
| Debts | 83,3 k € | +160.4% | 32,0 k € | |
Public limited company · Liège · incorporated on 10/04/2024
Public limited company loss-making in the latest fiscal year. Cash position rising (+99.0%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Key indicators
THAMEUS is a Public limited company incorporated in 2024. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Liège.